Subtype
Female Reproductive System Neoplasm
CI-CAN-00000885Explore in graph →
Non-malignant1,630 active trials11 approved drugs139 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000885Explore in graph →
Clinical trials
7,171 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01397877 | GINECO-EN102b - BKM120 as Monotherapy in the Treatment of Initial or Recurrent Metastatic Endometrial Cancer(ENDOPIK) | completed | Phase 2 | 24 | ARCAGY/ GINECO GROUPOTHER | 1 | Sep 6, 2023 | clinicaltrials |
| NCT01583322 | Vargatef in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Ovarian Cancer(CHIVA) | completed | Phase 2 | 188 | ARCAGY/ GINECO GROUPOTHER | 1 | Sep 6, 2023 |
| clinicaltrials |
| NCT01705158 | Myocet ® - Carboplatine in Ovarian Cancer in Relapse, Sensitive to the Platinum(MYCA) | completed | Phase 1 / Phase 2 | 87 | ARCAGY/ GINECO GROUPOTHER | 1 | Sep 6, 2023 | clinicaltrials |
| NCT02383251 | Paclitaxel/Pazopanib for Platinum Resistant/Refractory Ovarian Cancer(TAPAZ) | completed | Phase 2 | 118 | ARCAGY/ GINECO GROUPOTHER | 1 | Sep 6, 2023 | clinicaltrials |
| NCT02584465 | REGorafenib vsTamoxifen in Patients With Platinum-sensitive OVARian Carcinoma and Isolated Biological Progression(REGOVAR) | completed | Phase 2 | 68 | ARCAGY/ GINECO GROUPOTHER | 1 | Sep 6, 2023 | clinicaltrials |
| NCT04542356 | Study on the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia During Concurrent Chemoradiotherapy of Cervical Cancer | completed | Phase 2 | 60 | Chongqing University Cancer HospitalOTHER | 1 | Sep 6, 2023 | clinicaltrials |
| NCT00993655 | Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer | completed | Phase 2 | 275 | Canadian Cancer Trials GroupNETWORK | 4 | Aug 28, 2023 | clinicaltrials |
| NCT03180684 | Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3) | completed | Phase 2 | 33 | Inovio PharmaceuticalsINDUSTRY | 1 | Aug 25, 2023 | clinicaltrials |
| NCT04590248 | A Study of Adavosertib as Treatment for Uterine Serous Carcinoma(ADAGIO) | completed | Phase 2 | 109 | AstraZenecaINDUSTRY | 5 | Aug 14, 2023 | clinicaltrials |
| NCT00053794 | Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma | completed | Phase 2 | 17 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT00770185 | Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer | completed | Phase 2 | 35 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT03602079 | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | completed | Phase 1 / Phase 2 | 49 | Klus Pharma Inc.INDUSTRY | 1 | Aug 3, 2023 | clinicaltrials |
| NCT04669002 | EP0057 in Combination With Olaparib in Advanced Ovarian Cancer | completed | Phase 2 | 34 | Ellipses PharmaINDUSTRY | 3 | Aug 2, 2023 | clinicaltrials |
| NCT02988817 | Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 306 | GenmabINDUSTRY | 6 | Aug 1, 2023 | clinicaltrials |
| NCT05963334 | Comparison of Weekly Versus Every Three Weeks of Carboplatin Plus Paclitaxel in Patients With Advanced Epithelial Ovarian Cancer | completed | Phase 1 / Phase 2 | 49 | Cairo UniversityOTHER | 1 | Jul 27, 2023 | clinicaltrials |
| NCT03438396 | A Trial of Tisotumab Vedotin in Cervical Cancer | completed | Phase 2 | 102 | Seagen Inc.INDUSTRY | 8 | Jul 25, 2023 | clinicaltrials |
| NCT03735680 | A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer | completed | Phase 2 | 30 | OncoNano Medicine, Inc.INDUSTRY | 1 | Jul 7, 2023 | clinicaltrials |
| NCT04417192 | Olaparib Monotherapy and Olaparib + Pembrolizumab Combination Therapy for Ovarian Cancer(OLAPem) | completed | Phase 2 | 30 | National Cancer Center Hospital EastOTHER | 1 | Jul 6, 2023 | clinicaltrials |
| NCT00003308 | Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma | completed | Phase 2 | — | Eastern Cooperative Oncology GroupNETWORK | 4 | Jun 22, 2023 | clinicaltrials |
| NCT00003518 | Paclitaxel Plus Gemcitabine in Treating Patients With Refractory Metastatic Germ Cell Tumors | completed | Phase 2 | 44 | Eastern Cooperative Oncology GroupNETWORK | 2 | Jun 22, 2023 | clinicaltrials |
| NCT01111461 | Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression | completed | Phase 2 | 133 | Eisai Inc.INDUSTRY | 8 | Jun 22, 2023 | clinicaltrials |
| NCT01689714 | Safety and Efficacy of Folatescan (Technetium TC 99M EC20) in Patients With Suspected Ovarian Carcinoma or Recurrent Endometrial Carcinoma | completed | Phase 2 | 16 | EndocyteINDUSTRY | 0 | Jun 22, 2023 | clinicaltrials |
| NCT01891344 | A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)(ARIEL2) | completed | Phase 2 | 491 | pharmaand GmbHINDUSTRY | 6 | Jun 12, 2023 | clinicaltrials |
| NCT01482715 | A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II) | completed | Phase 1 / Phase 2 | 136 | pharmaand GmbHINDUSTRY | 5 | Jun 9, 2023 | clinicaltrials |
| NCT01367002 | Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer | completed | Phase 2 | 61 | Yale UniversityOTHER | 1 | May 17, 2023 | clinicaltrials |
| NCT03657043 | A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208) | completed | Phase 2 | 98 | Seagen Inc.INDUSTRY | 6 | May 6, 2023 | clinicaltrials |
| NCT00538031 | Cyclophosphamide With or Without Celecoxib in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 52 | City of Hope Medical CenterOTHER | 1 | Apr 21, 2023 | clinicaltrials |
| NCT05751629 | Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer(COHORT-A) | completed | Phase 2 | 41 | Tesaro, Inc.INDUSTRY | 1 | Apr 21, 2023 | clinicaltrials |
| NCT02740777 | Evaluating the 2-dose Immunization Schedule of Human Papillomavirus (HPV)-16/18 in Adolescent Females | completed | Phase 2 | 900 | Shanghai Zerun Biotechnology Co.,LtdINDUSTRY | 1 | Apr 13, 2023 | clinicaltrials |
| NCT03816553 | SHR-1210 in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical Cancer | completed | Phase 2 | 45 | Sun Yat-sen UniversityOTHER | 1 | Apr 11, 2023 | clinicaltrials |
| NCT03073525 | A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers | completed | Phase 2 | 25 | Gradalis, Inc.INDUSTRY | 1 | Apr 5, 2023 | clinicaltrials |
| NCT03427411 | M7824 in Subjects With HPV Associated Malignancies | completed | Phase 2 | 57 | National Cancer Institute (NCI)NIH | 1 | Mar 28, 2023 | clinicaltrials |
| NCT01399658 | Image-Guided Gynecologic Brachytherapy(AMIGO) | completed | Phase 2 | 93 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 14, 2023 | clinicaltrials |
| NCT02659384 | Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer | completed | Phase 2 | 122 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 5 | Mar 14, 2023 | clinicaltrials |
| NCT03287674 | TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer | completed | Phase 1 / Phase 2 | 7 | Inge Marie SvaneOTHER | 1 | Mar 1, 2023 | clinicaltrials |
| NCT02166905 | DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission | completed | Phase 1 / Phase 2 | 40 | Roswell Park Cancer InstituteOTHER | 1 | Feb 24, 2023 | clinicaltrials |
| NCT02549989 | Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 28 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 22, 2023 | clinicaltrials |
| NCT03366480 | A Study to Assess the Efficacy and Safety of ABTL0812(Endolung) | completed | Phase 1 / Phase 2 | 103 | Ability Pharmaceuticals SLINDUSTRY | 1 | Feb 22, 2023 | clinicaltrials |
| NCT03464201 | Enzalutamide in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors: GREKO III Study(GREKO III) | completed | Phase 2 | 16 | Grupo Español de Tumores Huérfanos e InfrecuentesOTHER | 1 | Feb 22, 2023 | clinicaltrials |
| NCT02921269 | Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer | completed | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Feb 21, 2023 | clinicaltrials |
| NCT03161132 | Resistant Ovarian Cancer, Olaparib and Liposomal Doxorubicin(ROLANDO) | completed | Phase 2 | 32 | Grupo Español de Investigación en Cáncer de OvarioOTHER | 1 | Jan 27, 2023 | clinicaltrials |
| NCT02025985 | Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies(SIGN) | completed | Phase 2 | 116 | Karyopharm Therapeutics IncINDUSTRY | 2 | Jan 26, 2023 | clinicaltrials |
| NCT04753216 | Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 3 | Northwestern UniversityOTHER | 1 | Jan 19, 2023 | clinicaltrials |
| NCT02963831 | A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies | completed | Phase 1 / Phase 2 | 67 | Ludwig Institute for Cancer ResearchOTHER | 1 | Dec 22, 2022 | clinicaltrials |
| NCT02657889 | Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer(TOPACIO) | completed | Phase 1 / Phase 2 | 122 | Tesaro, Inc.INDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT01693783 | Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer | completed | Phase 2 | 42 | National Cancer Institute (NCI)NIH | 2 | Nov 8, 2022 | clinicaltrials |
| NCT01097746 | First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer | completed | Phase 2 | 33 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 28, 2022 | clinicaltrials |
| NCT02866006 | Safety and Tolerability Evaluation Study of BVAC-C in Patients With HPV Type 16 or 18 Positive Cervical Cancer | completed | Phase 1 / Phase 2 | 32 | Cellid Co., Ltd.INDUSTRY | 1 | Oct 12, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Sep 6, 2023source: clinicaltrials